TY - JOUR
T1 - Potential and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision medicine in cancer
AU - Nuzzo, Silvia
AU - Roscigno, Giuseppina
AU - Affinito, Alessandra
AU - Ingenito, Francesco
AU - Quintavalle, Cristina
AU - Condorelli, Gerolama
PY - 2019/10
Y1 - 2019/10
N2 - Due to the progress made in the area of precision and personalized medicine in the field of cancer therapy, strategies to selectively and specifically identify target molecules causative of the diseases are urgently needed. Efforts are being made by a number of different laboratories, companies, and researchers to develop therapeutic molecules that selectively recognize the tissues and the cells of interest, exhibit few or no off-target and side effects, are non-immunogenic, and have a strong action. Aptamers, artificially selected single-stranded DNA or RNA oligonucleotides, are promising molecules satisfying many of the requirements needed for diagnosis and precision medicine. Aptamers can also couple to their native mechanism of action the delivery of additional molecules (oligonucleotides, siRNAs, miRNAs) to target cells. In this review, we summarize recent progress in the aptamer-mediated strategy for the specific delivery of therapeutic oligonucleotides.
AB - Due to the progress made in the area of precision and personalized medicine in the field of cancer therapy, strategies to selectively and specifically identify target molecules causative of the diseases are urgently needed. Efforts are being made by a number of different laboratories, companies, and researchers to develop therapeutic molecules that selectively recognize the tissues and the cells of interest, exhibit few or no off-target and side effects, are non-immunogenic, and have a strong action. Aptamers, artificially selected single-stranded DNA or RNA oligonucleotides, are promising molecules satisfying many of the requirements needed for diagnosis and precision medicine. Aptamers can also couple to their native mechanism of action the delivery of additional molecules (oligonucleotides, siRNAs, miRNAs) to target cells. In this review, we summarize recent progress in the aptamer-mediated strategy for the specific delivery of therapeutic oligonucleotides.
KW - Aptamers
KW - ASO
KW - Brain tumors
KW - Cancer therapy
KW - Diagnosis
KW - MiRNA
KW - RNAi
KW - ShRNA
KW - SiRNA
KW - Targeted delivery
UR - http://www.scopus.com/inward/record.url?scp=85073733139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073733139&partnerID=8YFLogxK
U2 - 10.3390/cancers11101521
DO - 10.3390/cancers11101521
M3 - Review article
AN - SCOPUS:85073733139
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 10
M1 - 1521
ER -